Anthos
Anthos Therapeutics is a clinical-stage biopharmaceutical company and a subsidiary of Novartis. Founded in 2019 by Blackstone Life Sciences, the company focuses on developing innovative anticoagulant therapies to improve cardiovascular care for vulnerable populations. The flagship product of Anthos is abelacimab, a fully human monoclonal antibody that acts as a Factor XI inhibitor. This investigational anticoagulant is designed to prevent blood clots while minimizing the risk of bleeding. Abelacimab is being developed in two formulations: a rapid-onset intravenous version for hospital use and
Investing activity
Anthos appears in 1 AI deal tracked by the AI Lounge deals desk, rounds totalling $90M. The rounds are mostly Series B, with a median round size of $90M. The most recent is Linq (Series B, $90M, Nov 2026).
Anthos most often invests alongside Andreessen Horowitz, Mucker Capital, Left Lane Capital and Abstract Ventures, and the companies it backs on AI Lounge are mostly in AI agent infrastructure.
Deals
Frequently asked questions about Anthos
What AI companies has Anthos invested in?
Anthos's AI investments include Linq. The 1 round on AI Lounge are listed on this page with amounts, dates and co-investors.
Where is Anthos based?
Anthos is based in Netherlands.
What stage does Anthos invest at?
In the rounds tracked on AI Lounge, Anthos has invested at Series B, with a median round of $90M.
Who does Anthos co-invest with?
Anthos's most frequent co-investors on AI Lounge are Andreessen Horowitz (1 deal), Mucker Capital (1 deal), Left Lane Capital (1 deal), Abstract Ventures (1 deal) and TQ Ventures (1 deal).
How can founders reach Anthos?
Founders on AI Lounge can see Anthos's contact details in AI Investor Contacts (paid plans), check for a warm introduction through members who worked with the firm under Warm Paths, and add Anthos to their Investor Pipeline to track the conversation.